The new Opioid Omnibus legislation is set to take effect on July 1, ushering in a host of changes to the Prescription Monitoring Program (PMP) as well as reforms that pertain to any practice or physician that prescribes schedule II-V controlled substances. It is likely that these sweeping reforms to controlled substance prescription will change the standard procedure for most physicians that prescribe medication. Some of the notable changes introduced by the bill include but are not limited to:
Healthcare providers most likely have questions pertaining to the implementation of the Opioid Omnibus Legislation. To assist providers in transitioning, the IMS has put together some practical answers to questions on the legislation.
Q: Will i need to register for the PMP on July 1, 2018?
A: No, Prescribers must register for the PMP at the time of renewing their Controlled Substance Act Registration.
Q: Does the existing chronic pain management CME mandate still apply if I am renewing my medical license after July 1, 2018?
A: No, it does not apply effective July 1, 2018. However, there is a requirement that Physicians, PAs, ARNPs, Dentists, and Podiatrists who prescribe opioids receive continuing education regarding the CDC Opioid Prescribing Guidelines as a condition to obtain their license.
Q: If I am renewing my medical license after July 1, 2018 do I need to meet the new CME requirements?
Q: How will the reforms to the PMP change how drug prescription is monitored?
A: Beginning February 1, 2019, the IBP will issue annual activity reports to all prescribers, detailing their controlled substance prescriptions from the previous year and a comparison with other prescribers of the same profession and specialty. The IBP is now authorized to issue targeted, proactive prescriber notifications of suspicious patient prescription activity. The IBP authority to respond to inappropriate prescribing practices is expanded to allow actions other than suspending, revoking, or refusing to renew a CSA registration.
To access the full list of regulatory changes that the Opioid Omnibus Legislation has inaugurated, click the "Official IMS Opioid Omnibus Policy Brief" Link at the bottom of the webpage.
IMS is committed to combatting physician burnout and professional resiliency, and creating collaboration opportunities in local settings throughout the year. We invite you to collaborate with physicians, clinic administrators, insurance regulators, a
IMS submitted written comments on hte proposed revisions to payment policies under Medicare Part B Physician Fee Schedule (PFS).
The new Opioid Omnibus Legislation, effective July 1, will change requirements for prescribers.
The Iowa Board of Medicine (IBM), at its June 8 meeting, voted to move forward with draft administrative rules to allow psychologists who have received additional pharmacology training to begin issuing prescriptions for psychotropic medications. Thes
In April the IMS membership elected new members to the IMS Board of Director. Meet newly elected IMS At-Large Director, Damon Dyche, MD.
Is there something you think we should be covering? What would you like to see IMS report on? Click here to let us know.